Leadership Changes at Novo Nordisk: A Strategic Move

Novo Nordisk has appointed Jamey Millar as the head of its U.S. business and Hong Chow as head of product and portfolio strategy. Millar, previously with UnitedHealth, will assume his role in February, while Chow, coming from Merck, will start later that month.

In a strategic shift, Danish pharmaceutical giant Novo Nordisk has announced leadership changes at its helm, appointing Jamey Millar as the new head of its U.S. operations and Hong Chow as head of product and portfolio strategy.

The transition is set to occur in February, with Millar stepping into his new role on the 5th, succeeding Dave Moore. Chow will begin her tenure on the 15th, replacing Ludovic Helfgott.

Millar, who was previously at UnitedHealth Group as CEO of Optum Specialty Holdings, and Chow, who comes from Merck Healthcare in Germany, are expected to bring their expertise to propel the company forward.